

MULPLETA (lusutrombopag)

Federal Employee Program.

RATIONALE FOR INCLUSION IN PA PROGRAM

Background

Mulpleta (lusutrombopag) is a thrombopoietin (TPO) receptor agonist used to increase platelet counts in patients with chronic liver disease prior to surgery in order to decrease the need for blood transfusions. Mulpleta is an orally bioavailable, small molecule TPO receptor agonist that interacts with the transmembrane domain of human TPO receptors expressed on megakaryocytes to induce the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells and megakaryocyte maturation (1).

Regulatory Status

FDA-approved indication: Mulpleta is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure (1).

Begin Mulpleta dosing 8-14 days prior to a scheduled procedure. The recommended dosage of Mulpleta is 3mg taken orally once daily with or without food for 7 days. Patients should undergo their procedure 2-8 days after the last dose. Mulpleta has been investigated only as a single 7-day once daily dosing regimen in clinical trials in patients with chronic liver disease. Mulpleta should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts (1).

The safety and effectiveness of Mulpleta in pediatric patients have not been established (1).

Summary

Mulpleta is a thrombopoietin (TPO) receptor agonist used to increase platelet counts in patients with chronic liver disease prior to surgery in order to decrease the need for blood transfusions. Begin Mulpleta dosing 8-14 days prior to a scheduled procedure. The recommended dosage of Mulpleta is 3mg taken orally once daily with or without food for 7 days. The safety and effectiveness of Mulpleta in pediatric patients have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate and cost-effective use of Mulpleta while maintaining optimal therapeutic outcomes.

References

1. Mulpleta [package insert]. Florham Park, NJ: Shionogi Inc.; April 2020.